Why the study?
A consensus process was needed to inform the development of a European shared decision support tool regarding the continuation or deprescribing of antithrombotic therapy in cancer patients at the end of life.
Population
Representative expert panel of physicians, pharmacists, nurses, and psychologists from eight European countries
Design
Three-round European Delphi study protocol
Authors
Loading...
May guide ATT decisions in cancer EOL care; leaves open practice change pending validation.
This protocol outlines a European Delphi study to develop a shared decision support tool for managing antithrombotic therapy in end-of-life cancer patients.
Deneche et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: